Review| Volume 131, ISSUE 4, P442.e1-442.e8, April 2018

Inflammation and Cardiovascular Disease Risk: A Case Study of HIV and Inflammatory Joint Disease

Published:December 18, 2017DOI:


      The epidemiologic data associating infection and inflammation with increased risk of cardiovascular disease is well established. Patients with chronically upregulated inflammatory pathways, such as those with HIV and inflammatory joint diseases, often have a risk of future cardiovascular risk that is similar to or higher than patients with diabetes. Thus, it is of heightened importance for clinicians to consider the cardiovascular risk of patients with these conditions. HIV and inflammatory joint diseases are archetypal examples of how inflammatory disorders contribute to vascular disease and provide illustrative lessons that can be leveraged in the prevention of cardiovascular disease. Managing chronic inflammatory diseases calls for a multifaceted approach to evaluation and treatment of suboptimal lifestyle habits, accurate estimation of cardiovascular disease risk with potential upwards recalibration due to chronic inflammation, and more intensive treatment of risk factors because current tools often underestimate the risk in this population. This approach is further supported by the recently published CANTOS trial demonstrating that reducing inflammation can serve as a therapeutic target among persons with residual inflammatory risk for cardiovascular disease.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Libby P.
        • Ridker P.M.
        • Hansson G.K.
        • Leducq Transatlantic Network on Atherothrombosis
        Inflammation in atherosclerosis: from pathophysiology to practice.
        J Am Coll Cardiol. 2009; 54: 2129-2138
        • Johnson A.S.
        • Song R.
        • Hall H.I.
        Estimated HIV incidence, prevalence, and undiagnosed infections in US states and Washington, DC, 2010-2014.
        J Acquir Immune Defic Syndr. 2017; 76: 116-122
        • Song R.
        • Hall H.I.
        • Green T.A.
        • Szwarcwald C.L.
        • Pantazis N.
        Using CD4 data to estimate HIV incidence, prevalence, and percent of undiagnosed infections in the United States.
        J Acquir Immune Defic Syndr. 2017; 74: 3-9
        • Cross M.
        • Smith E.
        • Hoy D.
        • et al.
        The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study.
        Ann Rheum Dis. 2014; 73: 1316-1322
        • Helmick C.G.
        • Lee-Han H.
        • Hirsch S.C.
        • Baird T.L.
        • Bartlett C.L.
        Prevalence of psoriasis among adults in the US: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys.
        Am J Prev Med. 2014; 47: 37-45
        • Ladak K.
        • Hashim J.
        • Clifford-Rashotte M.
        • Tandon V.
        • Matsos M.
        • Patel A.
        Cardiovascular risk management in rheumatoid arthritis: a large gap to close [e-pub ahead of print].
        Musculoskeletal Care. 2017;
        • Desai S.S.
        • Myles J.D.
        • Kaplan M.J.
        Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis.
        Arthritis Res Ther. 2012; 14: R270
        • Ridker P.M.
        • Everett B.M.
        • Thuren T.
        • et al.
        Antiinflammatory therapy with canakinumab for atherosclerotic disease.
        N Engl J Med. 2017; 377: 1119-1131
        • Ridker P.M.
        • Rifai N.
        • Clearfield M.
        • et al.
        Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
        N Engl J Med. 2001; 344: 1959-1965
        • Ridker P.M.
        Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?.
        Trans Am Clin Climatol Assoc. 2013; 124: 174-190
        • Choi H.K.
        • Hernan M.A.
        • Seeger J.D.
        • Robins J.M.
        • Wolfe F.
        Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.
        Lancet. 2002; 359: 1173-1177
        • Marks J.L.
        • Edwards C.J.
        Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity.
        Ther Adv Musculoskelet Dis. 2012; 4: 149-157
        • Greenberg J.D.
        • Kremer J.M.
        • Curtis J.R.
        • et al.
        Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.
        Ann Rheum Dis. 2011; 70: 576-582
        • Everett B.M.
        • Pradhan A.D.
        • Solomon D.H.
        • et al.
        Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.
        Am Heart J. 2013; 166 (e115): 199-207
        • Crittenden D.B.
        • Lehmann R.A.
        • Schneck L.
        • et al.
        Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.
        J Rheumatol. 2012; 39: 1458-1464
        • Fujisue K.
        • Sugamura K.
        • Kurokawa H.
        • et al.
        Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction.
        Circ J. 2017; 81: 1174-1182
        • Martinez G.J.
        • Robertson S.
        • Barraclough J.
        • et al.
        Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome.
        J Am Heart Assoc. 2015; 4 (e002128)
        • Vaidya K.
        • Arnott C.
        • Martinez G.J.
        • et al.
        Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT Coronary angiography study [e-pub ahead of print].
        JACC Cardiovasc Imaging. 2017;
        • Nidorf S.M.
        • Eikelboom J.W.
        • Budgeon C.A.
        • Thompson P.L.
        Low-dose colchicine for secondary prevention of cardiovascular disease.
        J Am Coll Cardiol. 2013; 61: 404-410
        • Hemkens L.G.
        • Ewald H.
        • Gloy V.L.
        • et al.
        Colchicine for prevention of cardiovascular events.
        Cochrane Database Syst Rev. 2016; (CD011047)
        • Ridker P.M.
        • Thuren T.
        • Zalewski A.
        • Libby P.
        Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
        Am Heart J. 2011; 162: 597-605
        • Libby P.
        Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond.
        J Am Coll Cardiol. 2017; 70: 2278-2289
        • Morton A.C.
        • Rothman A.M.
        • Greenwood J.P.
        • et al.
        The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.
        Eur Heart J. 2015; 36: 377-384
        • Ikonomidis I.
        • Tzortzis S.
        • Andreadou I.
        • et al.
        Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis.
        Circ Cardiovasc Imaging. 2014; 7: 619-628
        • Harrington R.A.
        Targeting inflammation in coronary artery disease.
        N Engl J Med. 2017; 377: 1197-1198
        • Bartlett D.B.
        • Connelly M.A.
        • AbouAssi H.
        • et al.
        A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls.
        Arthritis Res Ther. 2016; 18: 86
        • Calmy A.
        • Gayet-Ageron A.
        • Montecucco F.
        • et al.
        HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial.
        AIDS. 2009; 23: 929-939
        • Atehortua L.
        • Rojas M.
        • Vasquez G.M.
        • Castano D.
        Endothelial alterations in systemic lupus erythematosus and rheumatoid arthritis: potential effect of monocyte interaction.
        Mediators Inflamm. 2017; 2017 (9680729)
        • Habets K.L.
        • Trouw L.A.
        • Levarht E.W.
        • et al.
        Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis.
        Arthritis Res Ther. 2015; 17: 209
        • Lood C.
        • Tyden H.
        • Gullstrand B.
        • et al.
        Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus.
        PLoS One. 2014; 9: e99386
        • O'Brien M.
        • Montenont E.
        • Hu L.
        • et al.
        Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.
        J Acquir Immune Defic Syndr. 2013; 63: 280-288
        • Samji H.
        • Cescon A.
        • Hogg R.S.
        • et al.
        Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.
        PLoS One. 2013; 8: e81355
        • Hanna D.B.
        • Ramaswamy C.
        • Kaplan R.C.
        • et al.
        Trends in cardiovascular disease mortality among persons with HIV in New York City, 2001-2012.
        Clin Infect Dis. 2016; 63: 1122-1129
        • Triant V.A.
        • Lee H.
        • Hadigan C.
        • Grinspoon S.K.
        Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.
        J Clin Endocrinol Metab. 2007; 92: 2506-2512
        • Losina E.
        • Hyle E.P.
        • Borre E.D.
        • et al.
        Projecting 10-yr, 20-yr and lifetime risks of cardiovascular disease in persons living with HIV in the US.
        Clin Infect Dis. 2017; 65: 1266-1271
        • Post W.S.
        • Budoff M.
        • Kingsley L.
        • et al.
        Associations between HIV infection and subclinical coronary atherosclerosis.
        Ann Intern Med. 2014; 160: 458-467
        • Zanni M.V.
        • Abbara S.
        • Lo J.
        • et al.
        Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men.
        AIDS. 2013; 27: 1263-1272
        • Maggi P.
        • Bellacosa C.
        • Leone A.
        • et al.
        Cardiovascular risk in advanced naive HIV-infected patients starting antiretroviral therapy: comparison of three different regimens—PREVALEAT II cohort.
        Atherosclerosis. 2017; 263: 398-404
        • Rahmanian S.
        • Wewers M.E.
        • Koletar S.
        • Reynolds N.
        • Ferketich A.
        • Diaz P.
        Cigarette smoking in the HIV-infected population.
        Proc Am Thorac Soc. 2011; 8: 313-319
        • Liang J.S.
        • Distler O.
        • Cooper D.A.
        • et al.
        HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.
        Nat Med. 2001; 7: 1327-1331
        • Petit J.M.
        • Duong M.
        • Florentin E.
        • et al.
        Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study.
        J Lipid Res. 2003; 44: 1692-1697
        • Wang X.
        • Chai H.
        • Yao Q.
        • Chen C.
        Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction.
        J Acquir Immune Defic Syndr. 2007; 44: 493-499
        • Haissman J.M.
        • Haugaard A.K.
        • Knudsen A.
        • et al.
        Marker of endothelial dysfunction asymmetric dimethylarginine is elevated in hiv infection but not associated with subclinical atherosclerosis.
        J Acquir Immune Defic Syndr. 2016; 73: 507-513
        • Durand M.
        • Sheehy O.
        • Baril J.G.
        • Lelorier J.
        • Tremblay C.L.
        Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database.
        J Acquir Immune Defic Syndr. 2011; 57: 245-253
        • Mulligan K.
        • Grunfeld C.
        • Tai V.W.
        • et al.
        Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.
        J Acquir Immune Defic Syndr. 2000; 23: 35-43
        • Worm S.W.
        • Sabin C.
        • Weber R.
        • et al.
        Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
        J Infect Dis. 2010; 201: 318-330
        • Wu G.C.
        • Liu H.R.
        • Leng R.X.
        • et al.
        Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis.
        Autoimmun Rev. 2016; 15: 22-37
        • Tektonidou M.G.
        • Kravvariti E.
        • Konstantonis G.
        • Tentolouris N.
        • Sfikakis P.P.
        • Protogerou A.
        Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis.
        Autoimmun Rev. 2017; 16: 308-312
        • Schieir O.
        • Tosevski C.
        • Glazier R.H.
        • Hogg-Johnson S.
        • Badley E.M.
        Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis.
        Ann Rheum Dis. 2017; 76: 1396-1404
        • Lindhardsen J.
        • Ahlehoff O.
        • Gislason G.H.
        • et al.
        The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study.
        Ann Rheum Dis. 2011; 70: 929-934
        • van Halm V.P.
        • Peters M.J.
        • Voskuyl A.E.
        • et al.
        Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation.
        Ann Rheum Dis. 2009; 68: 1395-1400
        • Roman M.J.
        • Shanker B.A.
        • Davis A.
        • et al.
        Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.
        N Engl J Med. 2003; 349: 2399-2406
        • Yurkovich M.
        • Vostretsova K.
        • Chen W.
        • Avina-Zubieta J.A.
        Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.
        Arthritis Care Res (Hoboken). 2014; 66: 608-616
        • Mehta N.N.
        • Azfar R.S.
        • Shin D.B.
        • Neimann A.L.
        • Troxel A.B.
        • Gelfand J.M.
        Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General practice research database.
        Eur Heart J. 2010; 31: 1000-1006
        • Wibetoe G.
        • Ikdahl E.
        • Rollefstad S.
        • et al.
        Cardiovascular disease risk profiles in inflammatory joint disease entities.
        Arthritis Res Ther. 2017; 19: 153
        • Boyer J.F.
        • Gourraud P.A.
        • Cantagrel A.
        • Davignon J.L.
        • Constantin A.
        Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis.
        Joint Bone Spine. 2011; 78: 179-183
        • Szabo M.Z.
        • Szodoray P.
        • Kiss E.
        Dyslipidemia in systemic lupus erythematosus.
        Immunol Res. 2017; 65: 543-550
        • Zhang C.Y.
        • Lu L.J.
        • Li F.H.
        • et al.
        Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.
        J Clin Rheumatol. 2009; 15: 111-116
        • Ozkan S.G.
        • Yazisiz H.
        • Behlul A.
        • Gokbelen Y.A.
        • Borlu F.
        • Yazisiz V.
        Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis.
        Eur J Rheumatol. 2017; 4: 40-45
        • Choy E.
        • Sattar N.
        Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions.
        Ann Rheum Dis. 2009; 68: 460-469
        • Navarro-Millan I.
        • Charles-Schoeman C.
        • Yang S.
        • et al.
        Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.
        Arthritis Rheum. 2013; 65: 1430-1438
        • Davis 3rd, J.M.
        • Maradit Kremers H.
        • Crowson C.S.
        • et al.
        Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study.
        Arthritis Rheum. 2007; 56: 820-830
        • Feinstein M.J.
        • Nance R.M.
        • Drozd D.R.
        • et al.
        Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the centers for AIDS research network of integrated clinical systems.
        JAMA Cardiol. 2017; 2: 155-162
        • Raggi P.
        • De Francesco D.
        • Manicardi M.
        • et al.
        Prediction of hard cardiovascular events in HIV patients.
        J Antimicrob Chemother. 2016; 71: 3515-3518
        • Urowitz M.B.
        • Ibanez D.
        • Su J.
        • Gladman D.D.
        Modified framingham risk factor score for systemic lupus erythematosus.
        J Rheumatol. 2016; 43: 875-879
        • Arts E.E.
        • Popa C.D.
        • Den Broeder A.A.
        • et al.
        Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms.
        Ann Rheum Dis. 2016; 75: 674-680
        • Solomon D.H.
        • Greenberg J.
        • Curtis J.R.
        • et al.
        Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study.
        Arthritis Rheumatol. 2015; 67: 1995-2003
        • Agca R.
        • Heslinga S.C.
        • Rollefstad S.
        • et al.
        EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
        Ann Rheum Dis. 2017; 76: 17-28
        • Vos A.G.
        • Idris N.S.
        • Barth R.E.
        • Klipstein-Grobusch K.
        • Grobbee D.E.
        Pro-inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review.
        PLoS One. 2016; 11: e0147484
        • Zhang J.
        • Chen L.
        • Delzell E.
        • et al.
        The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.
        Ann Rheum Dis. 2014; 73: 1301-1308
        • Yousuf O.
        • Mohanty B.D.
        • Martin S.S.
        • et al.
        High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?.
        J Am Coll Cardiol. 2013; 62: 397-408
        • Kim J.
        • McEvoy J.W.
        • Nasir K.
        • et al.
        Critical review of high-sensitivity C-reactive protein and coronary artery calcium for the guidance of statin allocation: head-to-head comparison of the JUPITER and St. Francis Heart Trials.
        Circ Cardiovasc Qual Outcomes. 2014; 7: 315-322
        • Westhorpe C.L.
        • Schneider H.G.
        • Dunne M.
        • et al.
        C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals.
        Sex Health. 2014; 11: 580-582
        • Goodson N.J.
        • Symmons D.P.
        • Scott D.G.
        • Bunn D.
        • Lunt M.
        • Silman A.J.
        Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort.
        Arthritis Rheum. 2005; 52: 2293-2299
        • Polonsky T.S.
        • McClelland R.L.
        • Jorgensen N.W.
        • et al.
        Coronary artery calcium score and risk classification for coronary heart disease prediction.
        JAMA. 2010; 303: 1610-1616
        • Joshi P.H.
        • Blaha M.J.
        • Budoff M.J.
        • et al.
        The 10-year prognostic value of zero and minimal CAC.
        JACC Cardiovasc Imaging. 2017; 10: 957-958
        • McEvoy J.W.
        • Martin S.S.
        • Blaha M.J.
        • et al.
        The case for and against a coronary artery calcium trial: means, motive, and opportunity.
        JACC Cardiovasc Imaging. 2016; 9: 994-1002
        • Kao A.H.
        • Wasko M.C.
        • Krishnaswami S.
        • et al.
        C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis.
        Am J Cardiol. 2008; 102: 755-760
        • Kawai V.K.
        • Chung C.P.
        • Solus J.F.
        • Oeser A.
        • Raggi P.
        • Stein C.M.
        The ability of the 2013 American College of Cardiology/American Heart Association cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores.
        Arthritis Rheumatol. 2015; 67: 381-385
        • Miller P.E.
        • Haberlen S.A.
        • Metkus T.
        • et al.
        HIV and coronary arterial remodeling from the Multicenter AIDS Cohort Study (MACS).
        Atherosclerosis. 2015; 241: 716-722
        • Quinn T.
        • Bs M.F.
        • von Heideken J.
        • et al.
        Validity of the Nurses' health study physical activity questionnaire in estimating physical activity in adults with rheumatoid arthritis.
        BMC Musculoskelet Disord. 2017; 18: 234
        • de Lima L.R.A.
        • Silva D.A.S.
        • da Silva K.S.
        • Pelegrini A.
        • de Carlos Back I.
        • Petroski E.L.
        Aerobic fitness and moderate to vigorous physical activity in children and adolescents living with HIV.
        Pediatr Exerc Sci. 2017; 29: 377-387
        • O'Dwyer T.
        • Durcan L.
        • Wilson F.
        Exercise and physical activity in systemic lupus erythematosus: a systematic review with meta-analyses.
        Semin Arthritis Rheum. 2017; 47: 204-215
        • Matcham F.
        • Rayner L.
        • Steer S.
        • Hotopf M.
        The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis.
        Rheumatology (Oxford). 2013; 52: 2136-2148
        • Kelso-Chichetto N.E.
        • Okafor C.N.
        • Cook R.L.
        • Abraham A.G.
        • Bolan R.
        • Plankey M.
        Association between depressive symptom patterns and clinical profiles among persons living with HIV [e-pub ahead of print].
        AIDS Behav. 2017;
        • Al-Qubaeissy K.Y.
        • Fatoye F.A.
        • Goodwin P.C.
        • Yohannes A.M.
        The effectiveness of hydrotherapy in the management of rheumatoid arthritis: a systematic review.
        Musculoskeletal Care. 2013; 11: 3-18
        • Danninger K.
        • Hoppe U.C.
        • Pieringer H.
        Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?.
        Int J Rheum Dis. 2014; 17: 606-611
        • Yu H.H.
        • Chen P.C.
        • Yang Y.H.
        • et al.
        Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study.
        Atherosclerosis. 2015; 243: 11-18
        • Ou H.T.
        • Chang K.C.
        • Li C.Y.
        • Yang C.Y.
        • Ko N.Y.
        Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: a nation-wide longitudinal cohort study 2000-2011.
        Int J Cardiol. 2017; 230: 592-598
        • Rollefstad S.
        • Ikdahl E.
        • Hisdal J.
        • et al.
        Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study.
        Arthritis Rheumatol. 2015; 67: 1718-1728
        • Ikdahl E.
        • Hisdal J.
        • Rollefstad S.
        • et al.
        Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study.
        Arthritis Res Ther. 2015; 17: 279
        • Funderburg N.T.
        • Jiang Y.
        • Debanne S.M.
        • et al.
        Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.
        J Acquir Immune Defic Syndr. 2015; 68: 396-404
        • Calza L.
        • Vanino E.
        • Salvadori C.
        • et al.
        Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.
        HIV Clin Trials. 2014; 15: 1-13
        • Gilbert J.M.
        • Fitch K.V.
        • Grinspoon S.K.
        HIV-related cardiovascular disease, statins, and the REPRIEVE trial.
        Top Antivir Med. 2015; 23: 146-149
        • Lloyd-Jones D.M.
        • Morris P.B.
        • Ballantyne C.M.
        • et al.
        2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
        J Am Coll Cardiol. 2017; 70: 1785-1822
        • Guirguis-Blake J.M.
        • Evans C.V.
        • Senger C.A.
        • O'Connor E.A.
        • Whitlock E.P.
        Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force.
        Ann Intern Med. 2016; 164: 804-813
        • Duran J.
        • Peloquin C.
        • Zhang Y.
        • Felson D.T.
        Primary prevention of myocardial infarction in rheumatoid arthritis using aspirin: a case-crossover study and a propensity score-matched Cohort Study.
        J Rheumatol. 2017; 44: 418-424
        • Fasano S.
        • Pierro L.
        • Pantano I.
        • Iudici M.
        • Valentini G.
        Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus.
        J Rheumatol. 2017; 44: 1032-1038
        • Burkholder G.A.
        • Tamhane A.R.
        • Salinas J.L.
        • et al.
        Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients.
        Clin Infect Dis. 2012; 55: 1550-1557
        • Cote J.K.
        • Bili A.
        Aspirin use in rheumatoid arthritis patients with increased risk of cardiovascular disease.
        ISRN Rheumatol. 2013; 2013